Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2026)

Alx Oncology Holdings has reported Operating Expenses for 8 years, with the latest figure at $19.0 million in Q1 2026.

• Quarterly Operating Expenses fell 40.4% year-over-year to $19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.2 million (down 33.22% YoY) and the FY2025 annual result came in at $104.0 million, down 26.99% from the prior year.
• Operating Expenses declined to $19.0 million in Q1 2026 per ALXO's latest filing, from $23.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $53.3 million in Q3 2023 and troughed at $19.0 million in Q1 2026.
• A 5-year average of $33.1 million and a median of $32.2 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 107.31% in 2022, then slumped 40.4% in 2026.
• Over 5 years, Operating Expenses stood at $32.2 million in 2022, then surged by 49.05% to $48.0 million in 2023, then slumped by 36.25% to $30.6 million in 2024, then declined by 24.8% to $23.0 million in 2025, then fell by 17.61% to $19.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $19.0 million, $23.0 million, and $22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.